REPORTS
ㅤㅤAccessReportsㅤ ㅤ

At AELMHU, we produce quarterly and annual reports on access t
orphan drugs in Europe and Spain.
Clinical Trial Reports

AELMHU has published its Annual Report on Clinical Trials for Rare Diseases, which analyzes the trials authorized for these conditions.
Report on the Social Value of Human Rights

Report titled “Distinctive Features of Orphan Drugs and Their Value from a Social Perspective,” prepared by the Weber Foundation with the support of AELMHU.
NEWS
NEWS
January 14, 2026
AELMHU celebrates 15 years of commitment to people with rare diseases
The Spanish Association of Orphan and Ultra-Orphan Drug Laboratories (AELMHU) is celebrating its 15th anniversary, a milestone that reaffirms the commitment of pharmaceutical companies dedicated to researching and developing treatments for people with diseases … Read more
INTERVIEWS
ASSOCIATED COMPANIES
RESEARCH AND COMMITMENT to rare diseases

What is an orphan drug?
Orphan drugs (ODs) are innovative treatments, many of them biotechnological in origin, intended to diagnose, prevent, or treat patients with rare diseases for which there is no alternative therapy.




































































































